Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
Adakveo® - P-selectin inhibitor
NCT03474965 SOLACE-Kids (CSEG101B2201)
Indication
Sickle cell disease, pediatrics
Phase 2
PK/PD and safety of SEG101 at 5 mg/kg
Phase
Patients
100
Primary
Outcome
Measures
Arms
Conclusions
Neuroscience
Global Health
Intervention
Target
Patients
Readout
Milestone(s)
Publication
SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion +
Hydroxyurea/Hydroxycarbamide
Pediatric SCD patients with VOC
H2-2021 (pediatric patients ≥12 year old)
2024 (pediatric patients <12 year old)
1. Matthew M. Heeney, David C. Rees, Mariane de Montalembert, Isaac Odame,
R. Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Raquel Merino
Herranz, Julie Kanter; Study Design and Initial Baseline Characteristics in Solace-
Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood 2020;
136 (Supplement 1): 22-24. doi: https://doi.org/10.1182/blood-2020-137081
2. Matthew M. Heeney, David C. Rees, Mariane De Montalembert, Isaac Odame,
R. Clark Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Nadege Pfender,
Julie Kanter; Initial Safety and Efficacy Results from the Phase II, Multicenter,
Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell
Disease (SCD). Blood 2021; 138 (Supplement 1): 12. doi:
https://doi.org/10.1182/blood-2021-144730
87 Investor Relations | Q1 2023 Results
Appendix
References
Innovation: Clinical trials
Abbreviations
Oncology
Other
Biosimilars
1 NOVARTIS | Reimagining MedicineView entire presentation